 |
市場調査レポート
商品コード
818792
がん免疫療法の世界市場：市場規模・動向・業界分析 - 治療タイプ・新規標的・疾患タイプ・地域別 2020年～2025年Immuno Oncology Market Size, Trends, Industry Analysis By Treatment Approaches; By Novel Targets; By Tumor Types; By Region: Market Size & Forecast, 2020 - 2025 |
||||||
| がん免疫療法の世界市場：市場規模・動向・業界分析 - 治療タイプ・新規標的・疾患タイプ・地域別 2020年～2025年 |
|
出版日: 2020年04月01日
発行: Polaris Market Research
ページ情報: 英文 75 Pages
納期: 即日から翌営業日
|
- 全表示
- 概要
- 目次
世界のがん免疫療法の市場規模は、2025年までに388億9,000万米ドルに達すると予測されています。がん免疫療法は、体の自然な防御力を高めてがんの成長を抑制する生物学的治療法です。様々ながんの罹患率の上昇、がん免疫療法分野における技術進歩、従来のがん切除手術と比較した場合のアブレーション治療の利点に対する関心の高まりなどによって当市場の成長が促進される見通しです。
当レポートでは、世界のがん免疫療法市場を調査し、市場の概要、治療タイプ・新規標的・疾患タイプ・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、業界動向、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。
目次
第1章 イントロダクション
- レポート概要
第2章 エグゼクティブサマリー
第3章 調査手法
- 調査プロセス
- 調査手法
- 調査範囲と仮定
- 出典一覧
第4章 がん免疫療法市場の考察
- がん免疫療法：業界スナップショット
- 市場力学
- 市場影響要因
- 成長要因
- 阻害要因
- 市場機会の分析
- ファイブフォース分析
- PEST分析
第5章 がん免疫療法市場の分析と予測：治療タイプ別
- 市場規模：治療タイプ別
- モノクローナル抗体
- 市場規模（実績値・予測値）
- 治療用ワクチン
- チェックポイント阻害剤
- サイトカイン
第6章 がん免疫療法市場：新規標的別
- 市場規模：新規標的別
- IDO1i
- 市場規模：地域別（実績値・予測値）
- LAG-3 CPI
- 腫瘍溶解性ウイルス
- STINGアゴニスト
- TLRアゴニスト
- HDACi
- TIL
- VEGFi
- MEKi
- TIGIT
- CPI
- GITRアゴニスト
- TGF-b trap
- A2AR拮抗剤/CD73i
第7章 がん免疫療法市場：疾患タイプ別
- 市場規模：疾患タイプ別
- 黒色腫
- 市場規模：地域別（実績値・予測値）
- 非小細胞肺がん
- 腎細胞がん
- 頭頚部がん
- 膀胱がん
- 古典的ホジキンリンパ腫
- メルケル細胞がん
- その他
第8章 がん免疫療法市場：地域別
- イントロダクション
- 北米
- 市場規模：セグメント別（実績値・予測値）
- 米国
- カナダ
- メキシコ
- 欧州
- 市場規模：セグメント別（重量・金額ベース）
- ドイツ
- 英国
- アジア太平洋地域
- 市場規模：セグメント別（重量・金額ベース）
- 中国
- インド
- 日本
- 中南米
- 市場規模：セグメント別（重量・金額ベース）
- ブラジル
- 中東・アフリカ
- 市場規模：セグメント別（重量・金額ベース）
第9章 企業プロファイル
- Bristol Myers Squibb
- Merck & Co.
- AstraZeneca
- Roche Holding AG
- Pfizer Inc.
- Incyte Corporation
- Seattle Genetics
The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report "Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 - 2026" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body's natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.
The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO's, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.
On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin's Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin's lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.
On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.
Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.
Polaris Market research has segmented the Immuno-oncology market report on the basis of Treatment Approaches, novel targets, tumor types, and by region
Immuno-Oncology Treatment Approach Outlook (Revenue, USD Million, 2015 - 2025)
Monoclonal Antibodies
Therapeutic Vaccines
Checkpoint Inhibitors
Cytokines
Immuno-Oncology Novel Target Outlook (Revenue, USD Million, 2015 - 2025)
IDO1i
LAG-3 CPI
Oncolytic virus
STING agonist
TLR agonist
HDACi
TIL
VEGFi
MEKi
TIGIT
CPI
GITR agonist
TGF-b trap
A2AR antagonist/CD73i
Immuno-Oncology Tumor Type Outlook (Revenue, USD Million, 2015 - 2025)
Melanoma
Non-Small Cell Lung Cancer
Renal Cell Carcinoma
Head & Neck Cancer
Bladder Cancer
Classical Hodgkin's Lymphoma
Merkel Cell Carcinoma
Others
Immuno-Oncology Regional Outlook (Revenue, USD Million, 2015 - 2025)
North America
U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
India
Japan
Latin America
Mexico
Middle East & Africa
Table of Contents
Chapter 1. Introduction
- 1.1. Report Description
Chapter 2. Executive Summary
Chapter 3. Research Methodology Overview
- 3.1. Research Process
- 3.1.1. Information procurement
- 3.1.2. Purchased database:
- 3.1.3. Polaris Market Research's internal database
- 3.2. Research Methodology
- 3.3. Research Scope & Assumptions
- 3.4. List of Data Sources
Chapter 4. Market Insights
- 4.1. Immuno Oncology: Industry Snapshot
- 4.2. Market Dynamics
- 4.3. Immuno Oncology market Forces
- 4.3.1. Drivers
- 4.3.1.1. Increasing introduction of unconventional and advanced treatment techniques
- 4.3.1.2. Rapidly growing population of various cancer infected patients
- 4.3.2. Restraints
- 4.3.2.1. Limited access and awareness about immunotherapy
- 4.3.3. Opportunity analysis: Immunology-oncology market
- 4.3.3.1. Increasing demand for improved cancer care by patients
- 4.4. Porter's Five Forces Analysis
- 4.5. PEST Analysis: Immuno-Oncology Market
- 4.6. Five forces shaping the immuno-oncology market
Chapter 5. Immuno Oncology Market Estimates and Forecast, by Treatment Type
- 5.1. Market size by treatment type
- 5.2. Monoclonal Antibodies
- 5.2.1. Global immuno oncology monoclonal antibodies treatment market estimates & forecasts by region, 2015-2025
- 5.3. Therapeutic Vaccines
- 5.3.1. Global immuno oncology therapeutic vaccines treatment market estimates & forecasts by region, 2015-2025
- 5.4. Checkpoint Inhibitors
- 5.4.1. Global immuno oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2015-2025
- 5.5. Cytokines
- 5.5.1. Global immuno oncology cytokines treatment market estimates & forecasts by region, 2015-2025
Chapter 6. Immuno Oncology Market Estimates and Forecast, by Novel Target Type
- 6.1. Market size by novel target type
- 6.2. IDO1i
- 6.2.1. Global immuno oncology market estimates & forecasts for IDO1i target by region, 2015-2025
- 6.3. LAG-3 CPI
- 6.3.1. Global immuno oncology market estimates & forecasts for LAG-3 CPI target by region, 2015-2025
- 6.4. Oncolytic virus
- 6.4.1. Global immuno oncology market estimates & forecasts for Oncolytic virus target by region, 2015-2025
- 6.5. STING agonist
- 6.5.1. Global immuno oncology market estimates & forecasts for STING agonist target by region, 2015-2025
- 6.6. TLR agonist
- 6.6.1. Global immuno oncology market estimates & forecasts for TLR agonist target by region, 2015-2025
- 6.7. HDACi
- 6.7.1. Global immuno oncology market estimates & forecasts for HDACi target by region, 2015-2025
- 6.8. TIL
- 6.8.1. Global immuno oncology market estimates & forecasts for TIL target by region, 2015-2025
- 6.9. VEGFi
- 6.9.1. Global immuno oncology market estimates & forecasts for VEGFi target by region, 2015-2025
- 6.10. MEKi
- 6.10.1. Global immuno oncology market estimates & forecasts for MEKi target by region, 2015-2025
- 6.11. TIGIT
- 6.11.1. Global immuno oncology market estimates & forecasts for TIGIT target by region, 2015-2025
- 6.12. CPI
- 6.12.1. Global immuno oncology market estimates & forecasts for CPI target by region, 2015-2025
- 6.13. GITR agonist
- 6.13.1. Global immuno oncology market estimates & forecasts for GITR agonist target by region, 2015-2025
- 6.14. TGF-b trap
- 6.14.1. Global immuno oncology market estimates & forecasts for TGF-b trap target by region, 2015-2025
- 6.15. A2AR antagonist/CD73i
- 6.15.1. Global immuno oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2015-2025
Chapter 7. Immuno Oncology Market Estimates and Forecast, by Tumor or Cancer Type
- 7.1. Market size by tumor or cancer type
- 7.2. Melanoma
- 7.2.1. Global immuno oncology market estimates & forecasts for melanoma cancer by region, 2015-2025
- 7.3. Non-small cell lung cancer
- 7.3.1. Global immuno oncology market estimates & forecasts for non-small cell lung cancer by region, 2015-2025
- 7.4. Renal cell carcinoma
- 7.4.1. Global immuno oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2015-2025
- 7.5. Head, face & neck cancer
- 7.5.1. Global immuno oncology market estimates & forecasts for head, face & neck cancer by region, 2015-2025
- 7.6. Bladder cancer
- 7.6.1. Global immuno oncology market estimates & forecasts for bladder cancer by region, 2015-2025
- 7.7. Classical hodgkin's lymphoma
- 7.7.1. Global immuno oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2015-2025
- 7.8. Merkel cell carcinoma
- 7.8.1. Global immuno oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2015-2025
- 7.9. Other cancer types
- 7.9.1. Global immuno oncology market estimates & forecasts for other cancer types by region, 2015-2025
Chapter 8. Immuno Oncology Market Estimates and Forecast, by Region
- 8.1. Market size by region
- 8.2. North America
- 8.2.1. North America immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.2.2. North America immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.2.3. North America immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.2.4. U.S.
- 8.2.4.1. U.S. immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.2.4.2. U.S. immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.2.4.3. U.S. immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.2.5. Canada
- 8.2.5.1. Canada immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.2.5.2. Canada immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.2.5.3. Canada immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.2.6. Mexico
- 8.2.6.1. Mexico immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.2.6.2. Mexico immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.2.6.3. Mexico immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.3. Europe
- 8.3.1. Europe immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.3.2. Europe immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.3.3. Europe immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.3.4. Germany
- 8.3.4.1. Germany immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.3.4.2. Germany immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.3.4.3. Germany immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.3.5. UK
- 8.3.5.1. UK immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.3.5.2. UK immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.3.5.3. UK immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.4. Asia Pacific
- 8.4.1. Asia Pacific immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.4.2. Asia Pacific immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.4.3. Asia Pacific immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.4.4. China
- 8.4.4.1. China immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.4.4.2. China immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.4.4.3. China immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.4.5. India
- 8.4.5.1. India immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.4.5.2. India immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.4.5.3. India immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.4.6. Japan
- 8.4.6.1. Japan immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.4.6.2. Japan immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.4.6.3. Japan immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.5. Central & South America (CSA)
- 8.5.1. CSA immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.5.2. CSA immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.5.3. CSA immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.5.4. Brazil
- 8.5.4.1. Brazil immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.5.4.2. Brazil immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.5.4.3. Brazil immuno oncology market estimates & forecasts by tumor type, 2015-2025
- 8.6. Middle East & Africa (MEA)
- 8.6.1. MEA immuno oncology market estimates & forecasts by treatment type, 2015-2025
- 8.6.2. MEA immuno oncology market estimates & forecasts by novel target type, 2015-2025
- 8.6.3. MEA immuno oncology market estimates & forecasts by tumor type, 2015-2025
Chapter 9. Company Profiles
- 9.1. Bristol Myers Squibb
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Developments
- 9.2. Merck & Co.
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Developments
- 9.3. AstraZeneca
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Developments
- 9.4. Roche Holding AG
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Developments
- 9.5. Pfizer Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Developments
- 9.6. Incyte Corporation
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Developments
- 9.7. Seattle Genetics
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Developments
